Near-Fatal Asthma Attack Averted: Aggressive Treatment Prevents Intubation in Somalia
A 45-year-old woman with poorly controlled asthma in Somalia made a remarkable recovery from near-fatal hypercapnic respiratory failure thanks to swift and aggressive medical intervention, avoiding the need for endotracheal intubation or mechanical ventilation – a critical success in a resource-constrained setting.
Asthma is a chronic inflammatory disorder affecting the airways, characterized by recurring episodes of wheezing, shortness of breath, chest tightness, and coughing. Acute exacerbations, commonly known as asthma attacks, represent medical emergencies demanding prompt recognition and treatment. According to international guidelines from organizations like the Global Initiative for Asthma (GINA, 2024), the British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN, 2019), and the European Respiratory Society/American Thoracic Society (ERS/ATS, 2020), standard management of severe asthma attacks includes high-flow oxygen, repeated short-acting β2-agonists alongside anticholinergics, systemic corticosteroids, and intravenous magnesium sulfate. While mechanical ventilation can be life-saving in some cases, it carries significant risks and is best reserved for patients facing imminent respiratory failure.
Recent research, including a study by Althoff et al, suggests that noninvasive ventilation can improve outcomes for critically ill asthma patients and potentially reduce the need for intubation. However, in resource-limited environments like Somalia, where intensive care capacity is often stretched thin, severe asthma remains a major contributor to illness and death.
This case details the experience of a 45-year-old woman with a ten-year history of poorly managed bronchial asthma, marked by reliance on short-acting β2-agonists and inconsistent adherence to long-term maintenance therapy. She presented to the emergency department experiencing a sudden onset of severe dyspnea. She had no known cardiovascular or metabolic conditions, and due to limited diagnostic resources, had not undergone prior allergy testing or asthma phenotype assessment. The onset of her symptoms followed three days of fever, cough, rhinorrhea, and a sore throat, rapidly escalating to acute dyspnea and an inability to speak. Upon arrival, her Glasgow Coma Scale score was 9/15, and she exhibited severe respiratory distress. A physical examination revealed a “silent chest” – the absence of breath sounds – prominent use of accessory muscles, and gasping respirations, though peripheral pulses remained palpable.
Initial vital signs revealed critically low oxygen saturation (SpO2 of 47%), a rapid heart rate (130 beats per minute), blood pressure of 95/60 millimeters of mercury, a temperature of 36.8 degrees Celsius, and a random blood glucose level of 102 milligrams per deciliter.
The patient was immediately moved to the resuscitation area and treated as follows: manual ventilation was initiated using an oropharyngeal airway, an Ambu bag with a reservoir, and high-flow oxygen for five minutes, restoring SpO2 to 99%. Two large-bore intravenous cannulas were inserted, and intravenous fluids (Ringer’s lactate) were started. She received 125 mg of methylprednisolone and 40 mg of pantoprazole intravenously.
After the initial five minutes of bag-valve-mask ventilation, the patient was transitioned to nebulized bronchodilators – a combination of 5 mg of albuterol and 0.25 mg of ipratropium bromide administered every 20 minutes for three doses, alongside 0.5 mg of budesonide via inhalation. The head of her bed was elevated to a 45-degree angle.
Simultaneously, arterial blood gas (ABG), complete blood count (CBC), liver and renal function tests, and serum electrolyte levels were drawn. An electrocardiogram (ECG) showed sinus tachycardia, and a chest radiograph revealed hyperinflated lung fields consistent with acute asthma exacerbation, with no evidence of pneumonia or structural abnormalities.
The initial ABG analysis revealed severe respiratory acidosis (pH of 6.75), markedly elevated carbon dioxide levels (PaCO2 of 106.4 mmHg), and low oxygen levels (PaO2 of 67 mmHg). Repeat analysis showed significant improvement in both pH (7.26) and PaCO2 (50.8 mmHg), normalizing within 24 hours (pH 7.35, PaCO2 40.8 mmHg), reflecting a rapid clinical recovery. Leukocytosis (WBC 17.8 × 103/mm3) with neutrophilia (8.19 × 103/mm3) indicated an acute inflammatory response, while mild anemia developed during hospitalization (hemoglobin decreasing from 11.6 to 9.3 g/dL). Liver and renal function tests, electrolyte levels, and C-reactive protein remained within normal limits, confirming preserved systemic function throughout treatment.
Within one hour of vigorous resuscitation and close monitoring, the patient showed substantial improvement, regaining full alertness, conversing in complete sentences, and exhibiting bilateral wheezing upon auscultation instead of a silent chest. Oxygen saturation increased to 99% with supplemental oxygen.
Ceftriaxone 1 g IV was administered as empiric antibiotic coverage, along with 2g of intravenous magnesium sulfate over 20 minutes, and 8 mg of intravenous dexamethasone. The patient was admitted to the intensive care unit (ICU) for 24 hours of observation before being transferred to the pulmonology department.
After two days, she was discharged home with a prescription including 16 mg of methylprednisolone twice daily for five days, a fixed-dose inhaler containing 12 mcg of formoterol fumarate and 400 mcg of budesonide twice daily, 40 mg of pantoprazole once daily, and a Ventolin (salbutamol) inhaler for as-needed use.
Despite experiencing a life-threatening asthma attack and severe hypercapnic respiratory failure, the patient achieved a full recovery through rigorous medical intervention, successfully avoiding the need for endotracheal intubation or mechanical ventilation.
Severe and life-threatening asthma exacerbations demand immediate, evidence-based treatment. As outlined by GINA (2024), BTS/SIGN (2019), and ERS/ATS (2020), initial management should include high-flow oxygen, repeated high-dose inhaled short-acting β2-agonists (SABA), anticholinergics, systemic corticosteroids, and adjunctive therapies like intravenous magnesium sulfate for those not responding adequately to initial bronchodilators. Intubation and mechanical ventilation are reserved for cases of respiratory arrest, declining mental status, fatigue, or worsening acidosis and hypercapnia despite optimal treatment.
The patient’s presentation – a “quiet chest,” altered mental status, severe hypoxemia (SpO2 47%), and significant hypercapnia (PaCO2 106.4 mmHg) – typically necessitates immediate airway management. However, several factors contributed to her positive outcome without intubation. Vigorous resuscitation with high-concentration oxygen via bag-valve-mask ventilation quickly restored adequate oxygenation. The prompt administration of systemic corticosteroids (methylprednisolone), frequent nebulized bronchodilators (albuterol and ipratropium), and inhaled budesonide provided synergistic bronchodilation and early anti-inflammatory effects. Furthermore, intravenous magnesium sulfate, consistent with guideline recommendations, likely alleviated bronchospasm by promoting smooth muscle relaxation and enhancing bronchodilator efficacy.
Avoiding intubation in this case was particularly significant. While mechanical ventilation can be life-saving, it carries risks in severe asthma, including dynamic hyperinflation, barotrauma, and hypotension due to increased intrathoracic pressures. Current guidelines emphasize limiting intubation to patients experiencing imminent respiratory arrest or failing to respond to optimal medical treatment. In this patient, vigilant monitoring in the resuscitation bay, rapid escalation of pharmacological treatment, and physiological support within the first hour facilitated stabilization without the need for invasive airway management.
This case underscores the importance of early, aggressive, guideline-based treatment and meticulous monitoring in the emergency department. It also reinforces the crucial role of intravenous magnesium sulfate as an adjuvant in life-threatening asthma. Moreover, it highlights that select patients experiencing acute hypercapnia and acidosis can recover swiftly without intubation when treated promptly and comprehensively.
The limitations of this report include its single-case nature, which limits generalizability, the absence of long-term follow-up data, and the lack of advanced diagnostic testing due to resource constraints.
This case underscores that early, aggressive, guideline-based therapy can sometimes prevent intubation in life-threatening asthma. Clinicians, especially in resource-limited settings, should recognize that timely non-invasive management – systemic corticosteroids, frequent bronchodilators, and IV magnesium sulfate – can yield favorable outcomes and reduce complications from mechanical ventilation.
